Asia Beat: Japan's bioventure sector needs decisive action
This article was originally published in Scrip
Japan has been attempting to get its bioventure sector off the ground for as long as many in the industry can remember, certainly since I first started coming to the country more than 20 years ago. But progress continues to be glacially slow.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.